501 related articles for article (PubMed ID: 23644232)
41. Tuberous sclerosis--A model for tumour growth.
Dodd KM; Dunlop EA
Semin Cell Dev Biol; 2016 Apr; 52():3-11. PubMed ID: 26816112
[TBL] [Abstract][Full Text] [Related]
42. Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy.
Zhao W; Xie C; Zhang X; Liu J; Liu J; Xia Z
Brain Behav; 2023 Jun; 13(6):e2995. PubMed ID: 37221133
[TBL] [Abstract][Full Text] [Related]
43. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
44. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.
Ehninger D; Silva AJ
Trends Mol Med; 2011 Feb; 17(2):78-87. PubMed ID: 21115397
[TBL] [Abstract][Full Text] [Related]
45. Perfect match: mTOR inhibitors and tuberous sclerosis complex.
Luo C; Ye WR; Shi W; Yin P; Chen C; He YB; Chen MF; Zu XB; Cai Y
Orphanet J Rare Dis; 2022 Mar; 17(1):106. PubMed ID: 35246210
[TBL] [Abstract][Full Text] [Related]
46. Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy.
Mazumder AG; Padwad YS; Singh D
CNS Neurol Disord Drug Targets; 2016; 15(8):945-955. PubMed ID: 27306063
[TBL] [Abstract][Full Text] [Related]
47. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex.
Franz DN; Krueger DA
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):365-373. PubMed ID: 30307123
[TBL] [Abstract][Full Text] [Related]
48. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
49. Dysregulation of the TSC-mTOR pathway in human disease.
Inoki K; Corradetti MN; Guan KL
Nat Genet; 2005 Jan; 37(1):19-24. PubMed ID: 15624019
[TBL] [Abstract][Full Text] [Related]
50. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex.
Theilmann W; Gericke B; Schidlitzki A; Muneeb Anjum SM; Borsdorf S; Harries T; Roberds SL; Aguiar DJ; Brunner D; Leiser SC; Song D; Fabbro D; Hillmann P; Wymann MP; Löscher W
Neuropharmacology; 2020 Dec; 180():108297. PubMed ID: 32890589
[TBL] [Abstract][Full Text] [Related]
51. Mechanism-based treatment in tuberous sclerosis complex.
Jülich K; Sahin M
Pediatr Neurol; 2014 Apr; 50(4):290-6. PubMed ID: 24486221
[TBL] [Abstract][Full Text] [Related]
52. [Therapeutic update in tuberous sclerosis complex: the role of mTOR pathway inhibitors].
Ruiz-Falcó Rojas ML
Rev Neurol; 2012 May; 54 Suppl 3():S19-24. PubMed ID: 22605628
[TBL] [Abstract][Full Text] [Related]
53. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
54. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.
Palavra F; Robalo C; Reis F
Oxid Med Cell Longev; 2017; 2017():9820181. PubMed ID: 28386314
[TBL] [Abstract][Full Text] [Related]
55. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling.
van Veelen W; Korsse SE; van de Laar L; Peppelenbosch MP
Oncogene; 2011 May; 30(20):2289-303. PubMed ID: 21258412
[TBL] [Abstract][Full Text] [Related]
56. Modifying genetic epilepsies - Results from studies on tuberous sclerosis complex.
Jozwiak S; Kotulska K; Wong M; Bebin M
Neuropharmacology; 2020 Apr; 166():107908. PubMed ID: 31962286
[TBL] [Abstract][Full Text] [Related]
57. Astroglial calcium signaling and homeostasis in tuberous sclerosis complex.
Romagnolo A; Dematteis G; Scheper M; Luinenburg MJ; Mühlebner A; Van Hecke W; Manfredi M; De Giorgis V; Reano S; Filigheddu N; Bortolotto V; Tapella L; Anink JJ; François L; Dedeurwaerdere S; Mills JD; Genazzani AA; Lim D; Aronica E
Acta Neuropathol; 2024 Feb; 147(1):48. PubMed ID: 38418708
[TBL] [Abstract][Full Text] [Related]
58. Brain Symptoms of Tuberous Sclerosis Complex: Pathogenesis and Treatment.
Mizuguchi M; Ohsawa M; Kashii H; Sato A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206526
[TBL] [Abstract][Full Text] [Related]
59. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.
Jeong A; Wong M
J Child Neurol; 2018 Jan; 33(1):55-63. PubMed ID: 29246093
[TBL] [Abstract][Full Text] [Related]
60. Mammalian target of rapamycin: a central node of complex signaling cascades.
Dobashi Y; Watanabe Y; Miwa C; Suzuki S; Koyama S
Int J Clin Exp Pathol; 2011 Jun; 4(5):476-95. PubMed ID: 21738819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
